Drug description:

Solifenacin succinate is a urinary antispasmodic agent, belongs to anticholinergic class.
Solifenacin is indicated for the treatment for the relief of symptoms of urinary frequency, urinary urgency, or urge urinary incontinence associated with an overactive bladder.
It is formulated as tablets and film coated tablets and suspension for oral route of administration.

Mechanism of action:

Solifenacin is a competitive muscarinic receptor antagonist. Acetylcholine contracts the detrusor smooth muscle through muscarinic receptors of which the M3 subtype is predominantly involved. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.